COMPANY. Volastra Therapeutics, Inc. is a clinical-stage oncology biotech company based in New York City, pioneering novel approaches to treating cancer by targeting chromosomal instability (CIN), a unique vulnerability in cancer. Since its founding in 2019, Volastra has grown to support ongoing discovery efforts and a growing clinical organization. Our lead pipeline programs focus on two distinct inhibitors of KIF18A, a novel therapeutic target....
COMPANY. Volastra Therapeutics, Inc. is a clinical-stage oncology biotech company based in New York City, pioneering novel approaches to treating cancer by targeting chromosomal instability (CIN), a unique vulnerability in cancer. Since its founding in 2019, Volastra has grown to support ongoing discovery efforts and a growing clinical organization. Our lead pipeline programs focus on two distinct inhibitors of KIF18A, a novel therapeutic target....
COMPANY. Volastra Therapeutics, Inc. is a clinical-stage oncology biotech company based in New York City, pioneering novel approaches to treating cancer by targeting chromosomal instability (CIN), a unique vulnerability in cancer. Since its founding in 2019, Volastra has grown to support ongoing discovery efforts and a growing clinical organization. Our lead pipeline programs focus on two distinct inhibitors of KIF18A, a novel therapeutic target....
COMPANY. Volastra Therapeutics, Inc. is a clinical-stage oncology biotech company based in New York City, pioneering novel approaches to treating cancer by targeting chromosomal instability (CIN), a unique vulnerability in cancer. Since its founding in 2019, Volastra has grown to support ongoing discovery efforts and a growing clinical organization. Our lead pipeline programs focus on two distinct inhibitors of KIF18A, a novel therapeutic target....
COMPANY. Volastra Therapeutics, Inc. is a clinical-stage oncology biotech company based in New York City, pioneering novel approaches to treating cancer by targeting chromosomal instability (CIN), a unique vulnerability in cancer. Since its founding in 2019, Volastra has grown to support ongoing discovery efforts and a growing clinical organization. Our lead pipeline programs focus on two distinct inhibitors of KIF18A, a novel therapeutic target....
